{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-25-000033","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.032898+00:00","generated_at":"2026-05-21T05:37:57.997766+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Connect Biopharma Q1 net loss $10.3M; cash $84M; initiates two Phase 2 rademikibart trials","bullets":["Cash, equivalents and ST investments $84.0M as of March 31, 2025; runway into 2027.","Net loss $10.3M ($0.19/share) vs $8.7M ($0.16) in Q1 2024; R&D expense $6.6M, down $2.1M YoY.","Initiated Phase 2 Seabreeze STAT asthma and COPD studies for rademikibart; topline data expected 1H 2026.","Phase 2 data published in AJRCCM showed 420 mL FEV1 improvement vs placebo in eosinophilic asthma."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-25-000033","json":"https://secwatch.observer/filing/0001835268-25-000033.json","markdown":"https://secwatch.observer/filing/0001835268-25-000033.md","text":"https://secwatch.observer/filing/0001835268-25-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000033/0001835268-25-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000033/cntb-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:37:57.997766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}